PubRank

Antonio Coppola

Author PubWeight™ 30.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013 2.19
2 Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002 1.64
3 Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost 2010 0.98
4 Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica 2007 0.97
5 Haemophilia A: molecular insights. Clin Chem Lab Med 2007 0.96
6 Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost 2009 0.94
7 Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. Cochrane Database Syst Rev 2015 0.90
8 The infectious burden in atherothrombosis. Semin Thromb Hemost 2012 0.90
9 Acquired haemophilia a in the elderly: case reports. Curr Gerontol Geriatr Res 2010 0.89
10 Homocysteine and arterial thrombosis: Challenge and opportunity. Thromb Haemost 2010 0.89
11 Denaturing HPLC procedure for factor IX gene scanning. Clin Chem 2003 0.88
12 Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost 2012 0.86
13 Preventing postsurgical venous thromboembolism: pharmacological approaches. Semin Thromb Hemost 2011 0.85
14 Haemophilia B: from molecular diagnosis to gene therapy. Clin Chem Lab Med 2003 0.85
15 Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. Transfus Med 2011 0.84
16 No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. Thromb Res 2002 0.84
17 High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica 2006 0.82
18 Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis 2010 0.82
19 Patient preference for needleless factor VIII reconstitution device: the Italian experience. Int J Gen Med 2010 0.81
20 FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013 0.81
21 IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest 2015 0.81
22 Mouse embryonic stem cells that survive γ-rays exposure maintain pluripotent differentiation potential and genome stability. J Cell Physiol 2012 0.81
23 A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Blood Transfus 2011 0.80
24 Arthropathy in patients with moderate hemophilia a: a systematic review of the literature. Semin Thromb Hemost 2013 0.80
25 Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost 2015 0.80
26 Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia. Blood Transfus 2012 0.79
27 Non-O blood group as a risk factor for cerebral vein thrombosis. Thromb Haemost 2013 0.78
28 Predisposing factors in patients with early-onset cerebral vein thrombosis. Thromb Res 2004 0.78
29 Pregnancy in a woman with a history of Budd-Chiari syndrome treated by porto-systemic shunt, protein C deficiency and bicornuate uterus. Thromb Haemost 2006 0.77
30 Genotype-independent in vivo oxidative stress following a methionine loading test: maximal platelet activation in subjects with early-onset thrombosis. Thromb Res 2011 0.77
31 Acute coronary syndrome and severe haemophilia: an unusual association with challenging treatment. Thromb Haemost 2010 0.76
32 Recombinant factor VIIa in a patient with Glanzmann's thrombasthenia undergoing gynecological surgery: open issues in light of successful treatment. Thromb Haemost 2004 0.76
33 Urinary excretion of iPF(2α)-III predicts the risk of future thrombotic events. A 10-year follow-up. Thromb Res 2011 0.75
34 Target of prophylaxis in severe haemophilia: more than factor levels. Blood Transfus 2012 0.75
35 Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management. Semin Thromb Hemost 2012 0.75
36 Prenatal diagnosis of haemophilia: our experience of 44 cases. Clin Chem Lab Med 2013 0.75
37 The challenge of diagnosing pulmonary embolism in children, pregnant women, and elderly patients: a descriptive review of the literature. Semin Thromb Hemost 2011 0.75
38 Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis. Pediatr Hematol Oncol 2014 0.75
39 Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review. Thromb Haemost 2016 0.75
40 Thrombotic and hemorrhagic syndromes associated with autoimmunity and infection. Semin Thromb Hemost 2012 0.75
41 [Safety of use assessment in a radio-frequency medical device]. G Ital Med Lav Ergon 2014 0.75
42 XVI Convegno Triennale sui Problemi Clinici e Sociali dell'Emofilia e delle Malattie Emorragiche Congenite, Napoli, 9-12 Novembre 2017. Blood Transfus 2017 0.75
43 Compliance to MADIT and MUSTT criteria for implantable cardioverter defibrillator therapy in the pre-SCD-Heft and MADIT II era. Data from a multicenter Italian study. Int J Cardiol 2009 0.75
44 Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis. Clin Rheumatol 2011 0.75